Fig. 4.

Prognostic potentials of SMaRT genes. a–g) The prognostic performance of the BoNE-derived SMaRT genes is evaluated across diverse disease conditions (colon cancer, a; liver fibrosis, b; sepsis, c; idiopathic pulmonary fibrosis, d; kidney transplantation, e and f; inflammaging, g-left). Results are displayed as Kaplan Meier (KM) curves with significance (p values) as assessed by log-rank-test. A composite immune response score is computed using Boolean path #13 → 14 → 3 or C#13 alone, as indicated within each KM plot. Low score = “reactive”; high score = “tolerant”. A threshold is computed using StepMiner by searching three options (thr, thr ± noise margin) on the immune score to separate these two states. g-right) Scatterplot between all possible thresholds of the #13 → 14 → 3 composite score and -log10 of the p value from the log-rank test for both male (blue) vs female (pink) separately. Pvalues are significant above the red line (p = 0.05). See also Supplementary Fig. S9F for other cancers (breast, prostate, pancreas, glioblastoma, and bladder).